https://www.selleckchem.com/pr....oducts/Adriamycin.ht
Moreover, the underexpression of RBMX was determined to be significantly associated with a favorable overall survival rate among patients, while patients with an underexpression of both SRSF3 and RBMX is a subgroup of individuals with better prognoses than all other patients. These results suggest that the underexpression of SRSF3 and that of its target RBMX can be used as potential biomarkers to predict favorable overall survival among head and neck cancer patients.Recently, biological disease-modifying antirheumatic drugs (bDMARDs)
Like
Comment
Share
